Chelation Partners is developing a patented family of iron-binding molecules that selectively sequesters and shields only that iron in our body that is being accessed by microbial, pathogens during infection. In other words, it is a chemical “magnet” which denies iron access needed by all pathogenic microbes for their growth during infection. Their lead compound, DIBI, has shown excellent results in many preclinical studies including with antibiotic resistant infections.
1344 Summer Street
Halifax NS B3H 0A8